{"prompt": "['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-004', '(Sanofi Genzyme EFC14769)', '27 Jun 2018', 'the final day on which supplemental hemostatic or antithrombotic treatments are administered as', 'part of the perioperative treatment plan. Fitusiran dosing may be resumed at the next scheduled', 'visit following the Perioperative Evaluation Period at the discretion of the Investigator. If', 'multiple consecutive doses of fitusiran are withheld, the Investigator will consult with the study', 'Medical Monitor, who will determine if the patient may continue on study.', 'Perioperative assessments will be performed in patients undergoing surgery during the study as', 'described in Appendix (Section 11.2.2) and as scheduled in Table 10.', '6.7.', 'Management of Sepsis', 'Formal clinical guidelines do not currently recommend correction of low AT that is seen in the', 'setting of sepsis, citing a lack of evidence for improved outcomes and an increased risk of', 'bleeding. [8, 9]. If a clinical determination is made that AT correction is desirable for a fitusiran-', 'treated patient in the setting of sepsis, this may be initiated per Investigator discretion.', '6.8.', 'Contraceptive Requirements', 'All study patients will be male and there are no contraceptive requirements for this study except', 'where required per local regulations.', \"Details of fitusiran toxicology studies are presented in the Investigator's Brochure.\", '6.9.', 'Treatment Compliance', 'Compliance with scheduled clinic visits (Table 1), and patient use of eDiary to record data as', 'required, will be monitored by study staff over the 9-month treatment duration.', '6.10.', 'Alcohol Restrictions', 'Patients will be required to limit alcohol consumption throughout the course of the study. Alcohol is', 'limited to no more than 2 units (unit: 1 glass of wine [approximately 125 mL] = 1 measure of spirits', '(approximately 1 fluid ounce) = 1/2 pint of beer [approximately 284 mL]) per day (no more than', '14 units per week) for the duration of the study.', '7.', 'STUDY ASSESSMENTS', 'The Schedule of Assessments is provided in Table 1. Additional information on the collection of', 'study assessments will be detailed in the Study Manual.', '7.1.', 'Screening/Baseline Assessments', 'An informed consent form (ICF) or assent form that has been approved by the appropriate', 'Institutional Review Board (IRB)/Independent Ethics Committee (IEC) must be signed by the', 'patient (or legal guardian) before the Screening/Baseline procedures are initiated. All patients', '(or their legal guardians) will be given a copy of the signed and dated ICF and/or assent form.', 'Patient demographic and medical history will be obtained at Screening. Medical history must', 'include documentation of factor concentrate prescriptions (in the medical or pharmacy record)', 'and documentation of reported number of bleeding episodes over the last 6 months. Patients will', 'Property of the Sanofi Group - strictly confidential', '52', '(electronic 1.0)']['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-004', '(Sanofi Genzyme EFC14769)', '27 Jun 2018', 'be screened to ensure that they meet all of the inclusion criteria and none of the exclusion', 'criteria. Rescreening of patients is permitted with consultation of the study Medical Monitor.', 'To complement medical records, information regarding health resource use will be collected as', 'specified in the Schedule of Assessments (Table 1), including days missed from work/school (as', 'appropriate) and days not able to perform normal activities outside of work/school due to', 'hemophilia, physician office visits, hemophilia treatment site visits, emergency room visits', '(reason and number), hospitalizations (reason, dates of hospitalization and associated length of', 'stay).', '7.1.1.', 'Patient Education Module', 'Patients will be educated by Investigators or trained healthcare professionals on coagulation and', 'general considerations with regard to managing hemophilia in the clinical setting of lowered-AT.', 'This will be performed as specified in the Schedule of Assessments (Table 1).', '7.1.2.', 'Inhibitor Status', 'Patients inhibitor status will be determined as specified in the Schedule of Assessments (Table 1)', 'by Nijmegen modified Bethesda assay.', '7.1.3.', 'FibroScan or FibroTest/APRI', 'A FibroScan or FibroTest/APRI will be performed according to the Schedule of Assessments', '(Table 1) to rule out cirrhosis in patients with a history of Hepatitis C.', '7.2.', 'Efficacy Assessments', 'Bleeding Episode Definitions', 'A bleeding episode is defined as any occurrence of hemorrhage that requires administration of', 'factor concentrates or BPA infusion, eg, hemarthrosis, muscle, or mucosal bleeding episodes.', 'Since bleeding episodes are recorded as an efficacy assessment of fitusiran, these will not be', 'treated as AEs unless they meet any of the SAE criteria listed in Section 7.5.6.1.', 'The definition of bleeding episode types described below is based on consensus opinion of', 'International Society on Thrombosis and Hemostasis (ISTH) as reflected in a recent', 'publication.[10', 'The start time of a bleeding episode will be considered the time at which symptoms of a bleeding', 'episode first develop. Bleeding, or any symptoms of bleeding at the same location, that occurs', 'within 72 hours of the last injection used to treat a bleeding episode at that location will be', 'considered a part of the original bleeding event, and will count as one bleeding episode towards', 'the ABR. Any bleeding symptoms that begin more than 72 hours from the last injection used to', 'treat a bleeding episode at that location will constitute a new bleeding event.', 'A spontaneous bleeding episode is a bleeding event that occurs for no apparent or known reason,', 'particularly into the joints, muscles, and soft tissues.', 'A joint bleeding episode is characterized by an unusual sensation in the joint (\"aura\") in', 'combination with 1) increasing swelling, or warmth over the skin over the joint, 2) increasing', 'Property of the Sanofi Group - strictly confidential', '53', '(electronic 1.0)']\n\n###\n\n", "completion": "END"}